This is not the most recent version of the article. View current version (3 FEB 2016)
Idiotype vaccination for Non-Hodgkin lymphoma
Editorial Group: Cochrane Haematological Malignancies Group
Published Online: 19 JAN 2011
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
How to Cite
Ossendorf V, Cornely O, Draube A, Monsef I, Engert A, Skoetz N. Idiotype vaccination for Non-Hodgkin lymphoma (Protocol). Cochrane Database of Systematic Reviews 2011, Issue 1. Art. No.: CD008964. DOI: 10.1002/14651858.CD008964.
- Publication Status: New
- Published Online: 19 JAN 2011
This is not the most recent version of the article. View current version (03 FEB 2016)
This is the protocol for a review and there is no abstract. The objectives are as follows:
In order to evaluate the therapeutical benefit of idiotype vaccination in the treatment of NHL we will particularly analyse overall survival (OS) as the primary endpoint; as well as progression-free survival (PFS), response rate, treatment-related mortality, adverse events and quality of life as secondary endpoints. We will analyse these outcome parameters critically and systematically with respect to different vaccine formulations, dosages or time schedules in the experimental arm and placebo or no other treatment in the control arm.